Collegium Pharmaceutical (COLL) Total Current Liabilities (2014 - 2026)

Collegium Pharmaceutical has reported Total Current Liabilities for 13 years, with the latest figure at $589.9 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 26.96% year-over-year to $589.9 million in Q2 2026; TTM through Jun 2026 was $589.9 million, a 26.96% increase from a year earlier, with the FY2025 full-year figure at $440.0 million, down 13.64% from the prior year.
• Total Current Liabilities was $589.9 million for Q2 2026 at Collegium Pharmaceutical, up from $435.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $589.9 million in Q2 2026, with the low at $373.6 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $453.0 million, with a median of $449.7 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 82.99% in 2022, then retreated 13.64% in 2025.
• Over 5 years, Total Current Liabilities stood at $433.7 million in 2022, then advanced by 5.58% to $457.9 million in 2023, then grew by 11.27% to $509.5 million in 2024, then declined by 13.64% to $440.0 million in 2025, then soared by 34.05% to $589.9 million in 2026.
• The last three Total Current Liabilities figures came in at $589.9 million (Q2 2026), $435.0 million (Q1 2026), and $440.0 million (Q4 2025), per Business Quant data.